AcureX Therapeutics is a pharma company with a mission to halt major neurodegenerative diseases driven by impaired mitophagy, starting with Parkinson’s disease (PD). AcureX’s approach and founding intellectual property is based on a Stanford University breakthrough discovery that identified dysfunctional signaling to Miro1 as the key driver of mitophagy defects in both genetic and sporadic PD patients. Using this initial discovery, AcureX has built and validated a mitophagy drug discovery platform and a precision PD biomarker to accelerate drug development and de-risk clinical trials. Using this platform, AcureX has discovered proprietary targets and small-molecule drugs that reactivate mitophagy in both genetic and sporadic PD patients. AcureX is rapidly advancing three small molecule therapeutic programs along with a precision blood-based biomarker for patient stratification and target engagement. AcureX’s lead program has begun IND-enabling studies and will be entering the clinic in 2023. In addition to PD, AcureX has demonstrated value for this approach in other diseases where mitophagy is implicated, opening future market opportunities beyond PD and neurodegeneration.